Down 30% From Its High, Is SpaceX Stock a Buy Now?

SpaceX is flagged as significantly overvalued: it trades at ~111x 2025 sales ($2.08T market cap vs $18.7B revenue) and ~56x forward 2026 sales vs $36.9B revenue forecasts, despite only ~22% of revenue and 11% of profits coming from rockets. The article notes SpaceX posted a $4.3B net loss in 2025 (while citing Starlink as the primary, most profitable growth engine) and argues investors may need several earnings quarters to validate growth before buying. Overall, the message is risk/caution on entry after the stock is ~30% off its all-time high.

Analysis

This is less a SpaceX-specific call than a read-through on how much the market is still paying for Elon-linked optionality. The second-order loser is the broader late-stage private growth complex: if a flagship name is marked down, it tightens secondary pricing and makes incremental capital more expensive for adjacent satellite, launch, and AI infrastructure startups that depend on future funding rounds rather than current cash flow. Public-market beneficiaries are the obvious “real-earnings” growth names; the market tends to rotate toward assets where revenue is auditable and margin expansion is visible.

The key catalyst path is not days but the next 1-3 months of private-market color: any new financing terms, insider secondary prints, or disclosures on Starlink monetization will tell us whether this is a temporary valuation wobble or the start of a broader de-rating. The bear case only strengthens if growth decelerates while leverage rises; the primary falsifier is a re-acceleration in recurring connectivity revenue or evidence that direct-to-device/defense contracts are turning into a material revenue leg. On a 6-18 month view, the real risk is that capital markets stop assigning a scarcity premium to ‘must-own’ private mega-caps.

Contrarian view: the market may be underestimating how quickly a telecom-like cash-flow profile can emerge if Starlink becomes a global utility rather than a venture-style growth story. But until that shows up in hard numbers, the valuation relies on narrative more than proof. For listed investors, the cleaner expression is to favor profitable compounders over Musk-premium exposure, not to chase the private name itself.

Key Decisions for Investors

• No direct trade in SPCX: treat as a watchlist item until there is a verified secondary price, financing terms, or operating disclosure; absent that, the signal is too narrative-driven to underwrite.
• Short TSLA on strength versus a basket of profitable growth leaders over a 1-3 month horizon; thesis is that any de-rating in Musk-related optionality compresses the same ‘vision premium’ that supports TSLA's multiple. Falsify if TSLA prints materially stronger margins or guidance.
• If you need long exposure to secular growth, rotate toward NVDA instead of speculative long-duration names; use it as a quality-growth hedge against sentiment air pockets in private tech. Reassess if NVDA multiple compresses on weak datacenter orders.
• Set an alert for any SpaceX financing event or insider secondary at a lower implied valuation; that would be the cleanest confirmatory catalyst for a broader private-market reset.